You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 193 No. 2, July 12, 1965 TABLE OF CONTENTS
  JAMA
  •  Online Features
  ORIGINAL CONTRIBUTIONS
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Heparin Osteoporosis

George C. Griffith, MD; George Nichols, Jr., MD; John D. Asher, MD; Barry Flanagan, MD

JAMA. 1965;193(2):91-94.


Abstract

Studies of 117 patients on long-term sodium heparin therapy disclosed cumulative evidence of a relationship between prolonged use of large amounts of heparin and osteoporosis. No symptoms of osteoporosis developed in 107 who received 10,000 units of concentrated sodium heparin once daily or less for 1 to 15 years. Of ten treated daily with larger doses (15,000 to 30,000 units) for six months or longer, spontaneous fractures of vertebrae or ribs developed in six, and biopsies disclosed soft, bony matrix. Studies of rats on sufficient heparin therapy to triple clotting for ten days indicated that collagenolytic activity of rat-bone-cell homogenate increased two to four times, and the stability of the lysosome-like bodies in bone cells which contain collagenase appears to be decreased. If these observations are true, hyperheparin states, whether spontaneous or man-induced, may take their place in the small growing category of lysosomal diseases.



Author Affiliations

From the Department of Medicine, University of Southern California School of Medicine and Los Angeles County Hospital, Los Angeles, and the Department of Medicine, Harvard Medical School, and the Peter Bent Brigham Hospital, Boston.


Footnotes

Read in part before the annual meeting of the American Society for Clinical Investigation, Atlantic City, NJ, May 2, 1965.

Reprint requests to 1136 W 6th St—Suite 111, Los Angeles 90017 (Dr. Griffith).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Managing heparin anticoagulation in patients with prosthetic cardiac valves: balancing the risk
Shlebak and Malik
Heart 2009;95:1643-1645.
FULL TEXT  

Risk of Posttransfusion Hepatitis in the United States: A Prospective Cooperative Study
JAMA 1972;220:692-701.
ABSTRACT  

Anticoagulants in Treatment of Patients With Hip Fracture
Wessler and Avioli
JAMA 1968;204:140-144.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1965 American Medical Association. All Rights Reserved.